FindTrial
Sign In

Romdomized study to evaluate the renoprotective effects of clarithromycin for diabetic patients with microalbuminuria.

Romdomized study to evaluate the renoprotective effects of clarithromycin for diabetic patients with microalbuminuria. - The study of the renoprotective effects of clarithromycin for diabetic nephropathy.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000303
Enrollment
40
Registered
2005-12-30
Start date
2005-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

In the clarythromycin group, claruthromycin will be prescribed at 200mg/day. In control group, patients receive ordinary diet/excercise therapy and hypotensive agents including ACE inhibitor and ARB.

Sponsors

Okayama university graduate school of medicine, dentistry and pharmaceutical sciences, Department of medicine and clinical science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Diabetic patients with microalbuminuria (ACR(alb/Cr) is more than 100 microgram/mgCr, less than 300microgram/mgCr) 2.Diabetic duration is more than 5 years

Exclusion criteria

Exclusion criteria: 1.CHF 2.Severe liver and/or kidney dysfunction 3.History of allergic response to drugs

Design outcomes

Primary

MeasureTime frame
Urinary albumin excretion—

Secondary

MeasureTime frame
1.Inflammatory marker—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026